Additionally, EGFR Amp was linked to significantly worsened prognosis in all diffuse gliomas, IDH-wildtype diffuse gliomas, GBM, molecular GBM, and histologic grade 2 and 3 IDH-wildtype diffuse astrocytic gliomas. This evidence concerns the gene EGFR and glioblastoma.